Objective: Patients with schizophrenia are at risk of osteoporosis (OP) and fractures due to their lifestyle. In this study, it was aimed to compare the levels of osteopontin (OPN) marker, which has an important role in bone turnover and contributes to the osteoporotic process, in schizophrenia patients and the control group.

Material and Method: From this study, patients who applied to the psychiatry outpatient clinic of Atatürk Unıversty Research Hospital between June 2019 and September 2019 and / or who were diagnosed with schizophrenia between the ages of 18-65 years and who did not have a history of trauma and deformity for at least 2 months. The group consisted of 18-65 years old patients with no history of psychiatric, trauma and deformity, and similar people in terms of age, gender and educational background. The number of samples determined as a result of power analysis using the G * Power 3.1 program as 110 (control: 55, patient: 55). In serum samples taken from each of the patients diagnosed with schizophrenia, OPN levels were measured by the ELISA method.

Results: When the serum OPN levels of the control and patient groups were examined, no statistically significant difference was detected between the two groups.

Conclusion: In our study, OPN levels were similar in schizophrenia patients and control groups. We think that different mechanisms other than OPN may have an effect on the frequent occurrence of osteoporosis in schizophrenia.